Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Gastroenterology | Family Medicine

Clinical Trials: Crohn's Disease


A listing of clinical trials currently looking for volunteers to enroll in Crohn's Disease studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : University of Alabama at Birmingham

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Birmingham : University of Alabama at Birmingham

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Birmingham : Apex Clinical Trials

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Birmingham : University of Alabama at Birmingham

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Birmingham : Apex Clinical Trials

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Mobile :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Arizona

Little Rock : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Little Rock : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Phoenix :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Scottsdale : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Scottsdale : Pfizer Investigational Site

B0151003 Open-Label Extension Study

View More »

Tucson : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tucson : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Tucson : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tucson : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tucson : Visions Clinical Research - Tucson

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Tuscon : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Arkansas

Little Rock : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Little Rock : Preferred Research Partners

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Little Rock : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

California

Los Angeles : Gastrointestinal Bioscience

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Los Angeles : Gastrointestinal Bioscience

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Montebello : Paramount Medical Specialty

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Montebello : Paramount Medical Specialty

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Sacramento : Capital Gastroenterology Consultants Medical Group

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Sacramento : Capital Gastroenterology Consultants Medical Group

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Diego : Clinical Applications Laboratories Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Diego : Desta Digestive Disease Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Diego : Desta Digestive Disease Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Diego : Clinical Applications Laboratories Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Anaheim : Advanced Clinical Research Institute - Phase 1, LLC

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Anaheim : AGMG Endoscopy Center

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Anaheim : Anaheim Clinical Trials

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Francisco :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Glendale : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

La Jolla : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

La Jolla : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

La Jolla : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

La Jolla : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

La Mesa : Rokay Kamyar, MD Inc

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

La Mirada : Medvin Clinical Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Lakewood : Lakewood Primary Care Medical Group, Inc

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Long Beach : Alliance Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Long Beach : Collaborative Neuroscience Network, Inc.

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Los Angeles : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Los Angeles : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Los Angeles : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Los Angeles :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Oakland :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Orange : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Orange : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Redlands : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

San Carlos : Digestive Care Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

San Carlos : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

San Diego : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

San Diego : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

San Diego : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

San Diego : Precision Research Institute, LLC

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

San Diego : San Diego Clinical Trials

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

San Diego : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

San Diego :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

San Francisco : University of California at San Francisco

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

San Francisco : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

San Francisco : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

San Francisco : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

San Francisco : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

San Francisco : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

SanDiego : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Santa Monica : Southern California Medical Gastroenterology Group

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Whittier : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Colorado

Aurora : University of Colorado Health Sciences Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Aurora : University of Colorado Health Sciences Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Golden : Rocky Mountain Clinical Research, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Golden : Rocky Mountain Clinical Research, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lafayette : Gastroenterology of the Rockies

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lafayette : Gastroenterology of the Rockies

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Littleton : Arapahoe Gastroenterology Associates P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Littleton : Arapahoe Gastroenterology Associates P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lone Tree : South Denver Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lone Tree : South Denver Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pueblo : Lynn Institute of Pueblo

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pueblo : Lynn Institute of Pueblo

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Denver : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Denver : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Denver :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Lafayette : Gastroenterology of the Rockies

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Lafayette : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Lakewood : Rocky Mountain Gastroenterology Associates

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Lakewood : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lakewood : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lakewood : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Lakewood : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Littleton : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Littleton : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Littleton : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Littleton : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Lone Tree : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lone Tree : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Thornton : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Thornton : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Connecticut

Bristol : Connecticut Gastroenterology Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bristol : Connecticut Gastroenterology Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Hamden : Gastroenterology Center of Connecticut, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Hamden : Gastroenterology Center of Connecticut, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Bridgeport : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Hamden : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hamden : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hamden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamden : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Hartford :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New Haven : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

New Haven :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

District of Columbia

Washington : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Washington : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Florida

Gainesville : University of Florida

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Gainesville : University of Florida

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : University of Florida, Jacksonville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : East Coast Institute for Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : Borland-Groover Clinic

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : Borland-Groover Clinic

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : East Coast Institute for Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : University of Florida, Jacksonville

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Maitland : Center for Advanced Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Maitland : Center for Advanced Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Melbourne : Osler Clinical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Melbourne : Osler Clinical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Miami : University of Miami Miller School of Medicine

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Miami : University of Miami Miller School of Medicine

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New Smyrna Beach : United Medical Research Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New Smyrna Beach : United Medical Research Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Orlando : Internal Medicine Specialists

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Orlando : Compass Research LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Orlando : Internal Medicine Specialists

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Orlando : Compass Research LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tampa : University of South Florida

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tampa : West Wind'r Research & Development, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tampa : University of South Florida

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tampa : West Wind'r Research & Development, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Clearwater : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Clearwater : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Clearwater : Clinical Research of West Florida

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Crystal River : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Crystal River : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Deland : Avail Clinical Research, LLC

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Gainesville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Gainesville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Gainesville : Drug Shipment Address

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Gainesville : Shands Endoscopy Center

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Gainesville : Shands Hospital at the University of Florida

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Gainesville : Florida Medical Research Institute

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Gainesville :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Gainsville : Shands Medical Plaza and Cancer Institute

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Inverness : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Inverness : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Jacksonville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Jacksonville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jacksonville : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Jacksonville : Borland-Groover Clinic

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Jacksonville : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Kissimme : Gastroenterology Associates of Osceola

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Largo : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Lauderdale Lakes : Sunrise Medical Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Maitland : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Miami : Community Research Foundation, Inc

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Miami : Paramount Public Health & Research Management Services

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Miami : Jackson Memorial Hospital

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease

Miami :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Miami : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Miami : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Naples : Gastroenterology Group of Naples

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Naples : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Naples : Gastroenterology Group of Naples

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Naples : Gastroenterology Group of Naples

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

New Port Richey : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Orlando : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Orlando : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Port Orange : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Sanford : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sanford : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Tampa : Clinical Research of West Florida, Inc.

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Trinity : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Weston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Winter Park : Shafran Gastroenterology Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Winter Park : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Winter Park : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Winter Park : Shafran Gastroenterology Center

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Winter Park : Shafran Gastroenterology Center

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gasteroenterology Center

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Zephyrhills : Florida Medical Clinic, P.A.

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Georgia

Atlanta : Atlanta Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Atlanta : Atlanta Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Decatur : Atlanta Center for Gastroenterology, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Decatur : Atlanta Center for Gastroenterology, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Newnan : Digestive Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Newnan : Digestive Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Savannah : St. Joseph's/Candler Health System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Savannah : St. Joseph's/Candler Health System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Snellville : DLW Research System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Snellville : DLW Research System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Atlanta : Atlanta Gastroenterology Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Atlanta : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Atlanta : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Atlanta : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Atlanta : Atlanta Gastroenterology Associates

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

Atlanta : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Atlanta : Atlanta Gastroenterology Associates

Optimizing Cimzia in Crohn's Patients

Atlanta : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Atlanta : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Atlanta :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Decatur : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Decatur : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Decatur : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Decatur : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Macon : Gastroenterology Associates of Central Georgia

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Macon : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Macon : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Macon : Gastroenterology Associates of Central Georgia, LLC

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Marietta : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Marietta : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Suwanee : Atlanta Gastroenterology Specialists, PC

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Idaho

Boise : Selah Medical Center

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Boise :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Illinois

Chicago : Rush University Medical Center - Treatment Research Center

Dysbiosis in inflammatory bowel disease.

Chicago : University of Chicago Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chicago : Rush University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chicago : University of Chicago Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chicago : Rush University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Urbana : Carle Clinic Association P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Urbana : Carle Clinic Association P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Arlington Heights : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Arlington Heights : Northwest Gastroenterologists

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Bolingbrook : Suburban Clinical Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Burr Ridge : Suburban Clinical Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Chicago : University of Chicago Hospital Medical Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chicago : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Chicago : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chicago : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chicago : University of Chicago Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chicago : University of Chicago

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chicago : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Chicago : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Chicago :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Evanston : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Evanston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Glenview : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Indiana

Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Anderson : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Evansville : Medisphere Medical Research Center, LLC

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Indianapolis : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Indianapolis : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Indianapolis : IU School of Medicine - Gastroenterology

PillCam® Platform With the PillCam Crohn's Disease Capsule

Iowa

Clive : Digestive & Liver Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Clive : Iowa Digestive Disease Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Clive : Iowa Digestive Disease Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Clive : Digestive & Liver Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Clive : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Clive : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Clive : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Kansas

Kansas City : University Of Kansas

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Kansas City : University Of Kansas

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Topeka : Cotton O'Neil Digestive Health Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Topeka : Cotton O'Neil Digestive Health Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Pratt : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Topeka : Cotton O'Neil Digestive Healthcare

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Kentucky

Lexington : University of Kentucky Chandler Medical Center

Crohn’s Disease Research Study

Lexington : University of Kentucky Chandler Medical Center

Does your Crohn's require surgery?

Lexington : University of Kentucky Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lexington : University of Kentucky Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Crestview Hills : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lexington : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lexington : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lexington : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lexington : University of Kentucky

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Lexington : University of Kentucky Chandler Medical Center

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Lexington : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lexington : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Louisville : University of Louisville School of Medicine

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Louisville : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Louisville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Louisiana

Baton Rouge : Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Baton Rouge : Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Baton Rouge : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Baton Rouge : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hammond : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hammond : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hammond : Gastroenterology Research Of New Orleans

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Hammond : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Monroe : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Monroe : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Monroe : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

New Orleans : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

New Orleans : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

New Orleans :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Maine

Portland :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Maryland

Chevy Chase : Metropolitan Gastroenterology Group, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research

Ulcerative Colitis and Crohn’s Disease (IBD) Research Study

Prince Frederick : Shah Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Prince Frederick : Shah Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Annapolis : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Annapolis : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Baltimore : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Baltimore : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Chevy Chase : Metropolitan Gastroenterology Group. PC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chevy Chase : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chevy Chase : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chevy Chase : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chevy Chase : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Chevy Chase : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Chevy Chase : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Towson : Endoscopic Microsurgery Associates PA

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Towson : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Towson : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Towson : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Massachusetts

Boston : Massachusetts General Hospital

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Boston : Boston Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Boston : Boston Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Boston : Massachusetts General Hospital

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Boston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Boston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Boston : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Boston : Tufts Medical Center

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Boston : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Boston : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Boston : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Boston :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Brockton : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Fall River : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Newton : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Worcester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Worcester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Worcester :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Michigan

Dearborn : The Center for Clinical Studies

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Dearborn : The Center for Clinical Studies

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Troy : Center for Digestive Health

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Troy : Center for Digestive Health

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Ann Arbor : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ann Arbor : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Ann Arbor : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ann Arbor : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ann Arbor : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Chesterfield : Clinical Research Institute of Michigan

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chesterfield : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chesterfield : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chesterfield : Clinical Research Institute of Michigan, LLC

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chesterfield : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chesterfield : Clinical Research Institute of Michigan, LLC

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Chesterfield : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Chesterfield : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Detroit :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Grand Rapids : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Kalamazoo : Beyer Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Novi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Novi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Troy : Center for Digestive Health

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Troy : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Troy : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Troy : Center for Digestive Health

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Troy : Surgical Centers of Michigan

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Troy : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Troy : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Troy : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Troy : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Troy : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Utica : Utica Surgery Center

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Wyoming : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Ypsilanti : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ypsilanti : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Minnesota

Plymouth : Minnesota Gastroenterology, P.A.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Plymouth : Minnesota Gastroenterology, P.A.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Rochester : Mayo Clinic

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Rochester : Mayo Clinic

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Minneapolis :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Rochester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Rochester : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Rochester : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Rochester :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Rochester : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Saint Paul :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

St. Paul : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

St. Paul : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Mississippi

Tupelo : Digestive Health Specialists

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tupelo : Digestive Health Specialists

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Ocean Springs : Digestive Health Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ocean Springs : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Ocean Springs : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Missouri

Kansas City : Truman Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Kansas City : Truman Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Mexico : Center for Digestive and Liver Diseases, Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Mexico : Center for Digestive and Liver Diseases, Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

St. Louis : Washington University

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

St. Louis : Washington University

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Columbia : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Columbia : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Kansas City : The Children's Mercy Hospital

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

Lees Summit : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lees Summit : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lee's Summit : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lee's Summit : Midwest Center for Clinical Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Lee'S Summit : Midwest Center For Clinical Research

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Mexico : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Mexico : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mexico : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Mexico : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Mexico : Center for Digestive and Liver Disease

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Mexico : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Saint Louis : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

St Louis : St Louis Center for Clinical Studies

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

St. Louis : Saint Louis Center for Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Studies

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Montana

Billings : Billings Clinic Research Center

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Nebraska

Boys Town :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Omaha : Quality Clinical Research, Inc.

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Nevada

Las Vegas : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Las Vegas : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sparks : Reno Clinical Trials

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

New Hampshire

Lebanon : Dartmouth-Hitchcock Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lebanon : Dartmouth-Hitchcock Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Lebanon : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lebanon : Dartmouth Hitchcock Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Lebanon : Dartmouth HItchcock Medical Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Manchester :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New Jersey

Morristown : Affiliates in Gastroenterology PA

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Morristown : Affiliates in Gastroenterology PA

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Vineland : The Gastroenterology Group of South Jersey

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Vineland : The Gastroenterology Group of South Jersey

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Berlin : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Blackwood : South Jersey Medical Associates, P.A.

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Egg Harbor : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Egg Harbor : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Egg Harbor Township : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Marlton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Marlton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mays Landing : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Mays Landing : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Mays Landing :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Morristown : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Morristown :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Teaneck : Holy Name Medical Center

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

New York

Bayside : Hepatobiliary Associates of New York

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bayside : Hepatobiliary Associates of New York

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Cheektowaga : Digestive Health Physician

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cheektowaga : Digestive Health Physician

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Great Neck : Long Island Clinical Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Great Neck : Long Island Clinical Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Merrick : Long Island Gastroenterology Group, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Merrick : Long Island Gastroenterology Group, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New York : Present Chapman Marion Steinlauf MD PC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New York : New York Presbyterian Hospital

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New York : Present Chapman Marion Steinlauf MD PC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New York : New York Presbyterian Hospital

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pittsford : Kim, Chung MD (Private Practice)

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pittsford : Kim, Chung MD (Private Practice)

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Rochester : University of Rochester

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Rochester : University of Rochester

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Setauket : Long Island Digestive Disease Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Setauket : Long Island Digestive Disease Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Stonybrook : SUNY Stony Brook University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Stonybrook : SUNY Stony Brook University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Syracuse : Syracuse Gastroenterological Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Syracuse : Syracuse Gastroenterological Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Albany : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Albany : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Brooklyn : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Brooklyn : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Brooklyn :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Brooklyn : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Buffalo :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Cheektowaga : Digestive Health Physicians

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Great Neck : Long Island Clinical Research Associates, LLP

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Great Neck : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Great Neck : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Great Neck : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Great Neck : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Great Neck : Long Island Clinical Research Associates, LLP

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Great Neck : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Great Neck : Long Island Clinical Research Assoc., Llp

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Great Neck : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Great Neck : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Lake Success : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Lake Success : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Mineola :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New Hyde Park :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New York : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

New York : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

New York : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

New York : Pfizer Investigational Site

B0151003 Open-Label Extension Study

New York : Metropolitan Research Associates

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New York : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

New York : Mount Sinai School of Medicine

Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Poughkeepsie : Premier Medical Group of the Hudson Valley, PC

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Poughkeepsie : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Poughkeepsie : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Rochester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Stony Brook : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Stony Brook :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Syracuse :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

North Carolina

Asheville : Asheville Gastroenterology Associates, P.A.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Asheville : Asheville Gastroenterology Associates, P.A.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chapel Hill : University of North Carolina at Chapel Hill

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chapel Hill : University of North Carolina at Chapel Hill

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Charlotte : Piedmont Medical Research

Crohn's Disease Study

Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Morganton : Burke Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Morganton : Burke Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Raleigh : Wake Research Associates

Crohn’s Disease Research Study

Raleigh : Wake Research Associates

Do you suffer from Crohn’s Disease?

Raleigh : Wake Research Associates

Study of Crohn's Disease Now Enrolling

Raleigh : Wake Research Associates

Treating your Crohn's disease doesn't have to be a solo act.

Winston Salem : Wake Forest University Baptist Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Winston Salem : Wake Forest University Baptist Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Chapel Hill : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chapel Hill : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chapel Hill : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chapel Hill : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Chapel Hill :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Chapel Hill : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Charlotte : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Charlotte : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Charlotte : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Durham : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Durham : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Durham : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Durham :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Raleigh : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Raleigh : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Raleigh : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Raleigh : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Raleigh : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Winston-Salem : Clinical Trials of America, Inc.

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Ohio

Beachwood : Gastroenterology Associates of Cleveland, Inc.

Research trial now enrolling for Humira ® for Crohn's Disease

Cincinnati : Consultants for Clinical Research Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cincinnati : Consultants for Clinical Research Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Cleveland : Cleveland Clinic Foundation

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cleveland : Cleveland Clinic Foundation

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Dayton : Dayton Science Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Dayton : Dayton Science Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Beavercreek : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Beavercreek : Dayton Gastroenterology

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

Cincinnati : Consultants for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati : Ohio Gastroenterology and Liver

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Cincinnati : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cincinnati : Consultants for Clinical Research, Inc

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Cincinnati : Consultants For Clinical Research

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Cleveland : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Columbus : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Columbus : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Dayton : Dayton Gastroenterology, Inc.

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Mentor : Great Lakes Gastroenterology

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Mentor : The Endoscopy Center of Lake County

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Mentor : Great Lakes Gastroenterology

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Oklahoma

Tulsa : Options Health Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tulsa : Options Health Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Norman : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oklahoma City : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Oklahoma City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Oklahoma City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oklahoma City : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Oklahoma City :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Oklahoma City, : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tulsa : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Tulsa : Gastroenterology United of Tulsa

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Tulsa : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tulsa : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Oregon

Eugene : Clinical Trials of America, Inc

Are you a man or woman over 18, with moderate to severe, active Crohn’s Disease?

Portland : The Oregon Clinic-West Hills Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Portland : The Oregon Clinic-West Hills Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Bend : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Bend : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Portland : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Portland : Northwest Gastroenterology Clinic, LLD

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Portland : Oregon Health & Science University

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

Portland : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Springfield : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Pennsylvania

Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Danville :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Hershey : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Indiana : Shirish A. Amin, MD, PC

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

King of Prussia : Omnicare Clinical Research, Inc.

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Philadelphia : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Philadelphia : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Philadelphia :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Pittsburg : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburg : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Pittsburgh : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburgh : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Pittsburgh : Children's Hospital of Pittsburgh of UPMC

Autologous Stem Cell Transplantation for Crohn's Disease

Pittsburgh : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Pittsburgh : University of Pittsburgh

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Sayre : Donald Guthrie Foundation for Education & Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Uniontown : Cherry Tree Medical

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Rhode Island

East Providence : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Warwick : Omega Medical Research

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

South Carolina

Charleston : Medical University Of SC CAR

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charleston : Medical University Of SC CAR

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Columbia : Consultants in Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Columbia : Consultants in Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Greenville :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

North Charleston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

North Charleston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tennessee

Germantown : Gastroenterology Center of the MidSouth, PC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Germantown : Gastroenterology Center of the MidSouth, PC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Knoxville :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Memphis :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Nashville : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Nashville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Nashville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nashville : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Nashville : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Nashville : Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University

Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Nashville : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Nashville : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Nashville : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Texas

Austin : Austin Gastroenterology, PA

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Austin : Austin Gastroenterology, PA

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Jacon Medical Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Gastroenterology Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Bayou City Research, Ltd.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Jacon Medical Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Bayou City Research, Ltd.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Gastroenterology Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pasadena : Digestive Health Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pasadena : Digestive Health Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Gastroenterology Clinic of San Antonio

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Stone Oak Research Foundation

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Stone Oak Research Foundation

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Gastroenterology Clinic of San Antonio

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tyler : Digestive Health Specialists of Tyler

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tyler : Digestive Health Specialists of Tyler

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Austin : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Austin : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Austin : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Austin : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Austin : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Austin : Austin Gastroenterology PA/Professional Quality Research, Inc

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Austin : Austin Gastroenterology PA/Professional Quality Research, Inc.

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Austin : Lovelace Scientific Resources, Inc.

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Dallas : Dallas VA Medical Center

Exacerbating Factors in Inflammatory Bowel Disease

Dallas :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Fort Worth :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Grapevine : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Grapevine : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Houston : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Houston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Houston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Houston : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Pasadena : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Pasadena : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

San Antonio : Gastroenterology Research Of San Antonio

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Sugar Land : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tyler : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Tyler : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tyler : Digestive Health Specialists of Tyler

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Tyler : Endoscopy Center of Tyler

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Utah

Sandy : Granite Peaks Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Sandy : Granite Peaks Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Ogden : Advanced Research Institute

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ogden : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Ogden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ogden : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Salt Lake City : University of Utah

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Salt Lake City : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Salt Lake City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Salt Lake City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Salt Lake City : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Vermont

Burlington :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Virginia

Charlottesville : University of Virginia Health System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charlottesville : University of Virginia Health System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Fairfax : Gastroenterology Associates of Northern Virginia

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Fairfax : Gastroenterology Associates of Northern Virginia

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Norfolk : Digestive and Liver Disease Specialist Ltd.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Norfolk : Digestive and Liver Disease Specialist Ltd.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Richmond : Hunter Holmes McGuire VA Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Richmond : Hunter Holmes McGuire VA Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Charlottesville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Charlottesville :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Chesapeake : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chesapeake : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Christiansburg : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Christiansburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Christiansburg : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Danville : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Danville : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Danville : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Fairfax : Gastroenterology Associates of Northern Virginia

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Fairfax :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Norfolk : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Norfolk : Cardiology Consultants

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Norfolk : Sentara Leigh Hospital

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Norfolk : Digestive and Liver Disease Specialists

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Norfolk : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Norfolk :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Richmond : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Richmond : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Virginia Beach : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Virginia Beach : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Washington

Bellevue : Northwest Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bellevue : Northwest Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Edmonds : Puget Sound Medical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Edmonds : Puget Sound Medical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Seattle : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Seattle : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seattle : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Seattle : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Seattle : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seattle : University of Washington Medical Center

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Seattle : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Seattle :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Seattle : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Wenatchee : Wenatchee Valley Medical Center

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

West Virginia

Morgantown : United BioSource Corporation

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Wisconsin

Madison : Pharmaseek, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Madison : Pharmaseek, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Medical College Of Wisconsin

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Medical College Of Wisconsin

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

View More »

Madison : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Madison : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Madison : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Madison : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Madison :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Milwaukee : The Center for Digestive Health

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Milwaukee : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Milwaukee : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Milwaukee : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Milwaukee :

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Wauwatosa : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Wauwatosa : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Australia

Adelaide : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Adelaide : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Adelaide : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Adelaide : Royal Adelaide Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Adelaide : Royal Adelaide Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

View More »

Adelaide : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Adelaide : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Adelaide : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Adelaide : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Bankstown : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bankstown : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bankstown : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Bedford Park : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Box Hill : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Brisbane : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Brisbane : QPharm

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Cairns : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Cairns : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Central Queensland M C : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Central Queensland M C : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Concord : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Concord : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Fitzroy : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Fitzroy : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fitzroy : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Fremantle : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Fremantle : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Fremantle : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Fremantle : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fremantle : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Garran : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Garran : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hersten : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hersten : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hersten : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Herston : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Herston : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Kingswood : Nepean Hospital

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Kurralta Park : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Liverpool : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Liverpool : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Malvern : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Malvern : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Melbourne : Royal Melbourne Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Melbourne : Royal Melbourne Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Melbourne : Center for Clinical Studies

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Parkville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Parkville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Parkville : The Royal Melbourne Hospital

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Prahran : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Prahran : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Prahran : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Prahran : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Austria

Innsbruck : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Oberpullendorf : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Oberpullendorf : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oberpullendorf : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

St Poelten : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

View More »

St. Veit/Glan : Krankenhaus

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Vienna : Site Reference ID/Investigator# 38145

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Wien : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Wien : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Wien : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Wien : Medizinische Universität

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Wien : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Wien : Pfizer Investigational Site

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs

Wien : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Belgium

Antwerp : UZ Antwerpen

Switching From Adalimumab to Infliximab

Belgium : Belgium

A Study of TRK-170 for the Treatment of Crohn's Disease

Bonheiden : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bonheiden : Site Reference ID/Investigator# 38147

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bonheiden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

View More »

Bonheiden : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Brussel : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Brussel : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Brussel : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Brussels : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Brussels : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Brussels : Pfizer Investigational Site

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs

Brussels : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Brussels : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Edegem : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Edegem : Site Reference ID/Investigator# 43966

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Genk : Hospital Oost-Limburg

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Gent : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Gent : Gent University Hospital

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Gent : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Gent : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Ghent : University Hospital Ghent

Switching From Adalimumab to Infliximab

Hasselt : Virga Jesse hospital

Switching From Adalimumab to Infliximab

Kortrijk : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kortrijk : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Kortrijk : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Kortrijk : AZ Groeninge

Switching From Adalimumab to Infliximab

Leuven : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Leuven : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Leuven : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Leuven : Leuven University Hospital

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Leuven : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Leuven : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Leuven : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Leuven : UZ Leuven

Switching From Adalimumab to Infliximab

Liege : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Liege : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Liege : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Mouscron : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Mouscron : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Oostende : AZ Damiaan

Switching From Adalimumab to Infliximab

Ottignies : Clinique Saint-Pierre

Switching From Adalimumab to Infliximab

Roeselare : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Roeselare : Hospital Hartziekenhuis

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Roeselare : Site Reference ID/Investigator# 38146

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Roeselare : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Roeselare : Heilig Hartziekenhuis Roeselare

Switching From Adalimumab to Infliximab

Brazil

Curitiba : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Curitiba : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Goiás : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ilha do Fundao - Rio de Janeiro : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Porto Alegre : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

View More »

Porto Alegre : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Porto Alegre : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rio De Janeiro : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Rio De Janeiro : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bulgaria

Bulgaria : Bulgaria

A Study of TRK-170 for the Treatment of Crohn's Disease

Pleven : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rousse : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sofia : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Varna : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Canada

Brandon : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Brandon : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Calgary : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Calgary : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Calgary : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Calgary : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Calgary : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Calgary : Site Reference ID/Investigator# 38156

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Calgary : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Calgary : Division of Gastroenterology

Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

Calgary : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Edmonton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Edmonton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Edmonton : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Edmonton : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Edmonton : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Halifax : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Halifax : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Halifax : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Halifax : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Halifax : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Hamilton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Hamilton : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hamilton : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Kingston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Kingston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kingston : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kingston : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

London : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

London : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

London : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

London : Pfizer Investigational Site

B0151003 Open-Label Extension Study

London : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

London : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Montreal : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Montreal : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Montreal : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Montreal : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Montreal : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Montreal : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Montreal : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Montreal : Innovaderm Research Inc.

Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab

Ottawa : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ottawa : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Ottawa : Investigational Site 5

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Quebec : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Quebec : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Quebec : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Toronto : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Toronto : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Toronto : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Toronto : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Toronto : Investigational Site 4

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Toronto : Investigational Site 1

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Vancouver : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Vancouver : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Vancouver : Site Reference ID/Investigator# 45502

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vancouver : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Vancouver : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Vancouver : Investigational Site 3

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Vaughan : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Vaughan : Site Reference ID/Investigator# 38155

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vaughan : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Victoria : Office of Dr. David C. Pearson

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Victoria : PerCuro Clinical Research Limited

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Victoria : Office of Drs. Ranjith Andrew Singh and Jamie D. Papp

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Winnipeg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Winnipeg : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Winnipeg : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Croatia

Avenija Gojka Suska 6 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osijek : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rijeka : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Zagreb : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Czech Republic

Brno : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Czech Republic : Czech Republic

A Study of TRK-170 for the Treatment of Crohn's Disease

Hradec Kralove : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Hradec Králové : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hradec Králové : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

View More »

Hradec Králové : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Hradec Kralove 12 : Site Reference ID/Investigator# 38159

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Olomouc : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Olomouc : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Olomouc : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Ostrava - Vitkovice : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ostrava - Vitkovice : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Prague 7 : Site Reference ID/Investigator# 38158

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Praha 10 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 10 : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Praha 4 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 4 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 4 : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Praha 7 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 7 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 7 : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Praha 9 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 9 : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Usti Nad Labem : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Denmark

Aalborg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Aalborg : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aalborg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aalborg : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Aarhus : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

View More »

Aarhus : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aarhus : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aarhus : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Aarhus C : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Aarhus C : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Herlev : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Herlev : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Herlev : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Herlev : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Herlev : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Hilleroed : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hilleroed : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Hvidovre : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hvidovre : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hvidovre : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Hvidovre : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hvidovre : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Koebenhavn : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koebenhavn NV : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koebenhavn NV : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Odense : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Odense : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Odense : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Silkeborg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Estonia

Tallinn : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tallinn : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tartu : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tartu : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

France

Amiens : Site Reference ID/Investigator# 38164

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amiens Cedex 1 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Amiens Cedex 1 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Amiens cedex 1 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amiens Cedex 1 : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

View More »

Bordeaux : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Caen Cedex 9 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Clichy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Clichy cedex : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Clichy cedex : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

France : France

A Study of TRK-170 for the Treatment of Crohn's Disease

Lille : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lille Cedex : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lille cedex : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lille Cedex : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Lille Cedex : Site Reference ID/Investigator# 38163

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lille cedex : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Marseille : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Nantes Cedex 1 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Nantes cedex 1 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Nice : Site Reference ID/Investigator# 42839

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Nice cedex 3 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Nice cedex 3 : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Paris : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Paris : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Paris : Hôpital Necker Enfants Malades, Faculté de Médecine Necker, INSERM EMI0212

Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis

Paris cedex 10 : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Paris cedex 10 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Paris cedex 10 : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Paris Cedex 12 : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Paris Cedex 12 : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Paris Cedex 18 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Pessac : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Pessac : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Pessac cedex : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Pessac Cedex : Site Reference ID/Investigator# 42818

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Pessac cedex : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Pessac cedex : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Reims : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Rouen : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Rouen : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Saint-Priest en Jarez : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Saint-Priest en Jarez : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Toulouse : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Vandoeuvre Les Nancy : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Vandoeuvre Les Nancy : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Vandoeuvre Les Nancy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Vandoeuvre Les Nancy : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Germany

Berlin : Novartis Investigative Site

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

Berlin : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Berlin : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Berlin : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Berlin : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

View More »

Berlin : Pfizer Investigational Site

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs

Berlin : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Berlin : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Berlin : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Bochum : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Bochum : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Braunschweig : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Braunschweig : Klinikum Braunscheweig

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Brinkum/Stuhr : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Erlangen : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Erlangen : Department of Medicine I, University of Erlangen-Nuremberg

Endomicroscopy in IBD Patients

Frankfurt Am Main : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Frankfurt Am Main : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Frankfurt am Main : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Frankfurt am Main : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Frankfurt/Main : Klinikum Frankfurt

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Freiburg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Halle : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Halle : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamburg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Hamburg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamburg : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hamburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamburg : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Hannover : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Hannover : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hannover : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hannover : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hannover : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Haßloch : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Heidelberg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Heidelberg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jena : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Jena : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kiel : Novartis Investigative Site

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

Kiel : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kiel : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Kiel : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kiel : Universitaetsklinikum Schleswig-Holstein

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Kiel : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Kiel : Site Reference ID/Investigator# 38170

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Ludwigshafen : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lÿneburg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lÿneburg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Magdeburg : Site Reference ID/Investigator# 38168

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Mannheim : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Mannheim : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Minden : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Minden : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Minden : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Minden : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Minden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Minden : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Muenster : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Munchen : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Munchen : Research Site

Safety Study of Entocort for Children With Crohn's Disease

München : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

München : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Münster : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nurnberg : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Nurnberg : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Regensburg : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Regensburg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Regensburg : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Regensburg : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Regensburg : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Stade : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ulm : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Ulm : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ulm : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ulm : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ulm : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Greece

Athens : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Athens : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hong Kong

Hong Kong : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Shatin, New Territories : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hungary

Bekescsaba : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bekescsaba : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bekescsaba : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Békéscsaba : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Budapest : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

View More »

Budapest : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Budapest : Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Budapest : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Budapest N/A : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Debrecen : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Debrecen : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Gyula : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hungary : Hungary

A Study of TRK-170 for the Treatment of Crohn's Disease

Miskolc : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Mosonmagyaróvár : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pecs : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Szeged : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Szekesfehervar : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Szekesfehervar : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Szekszard : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Szekszard : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Szekszard : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Szekszard : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Szekszárd : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Szekszárd : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Szekszárd : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Iceland

Reykjavik : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Reykjavik : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ireland

Dublin : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Dublin : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Dublin 4 : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Dublin 9 : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Dublin 9 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Israel

Ashkelon : Barzilai Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Haifa : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Haifa : Rambam Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Haifa : Bnai Zion Hospital

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Holon : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

View More »

Holon : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Israel : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Israel : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Jerusalem : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Jerusalem : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Jerusalem : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jerusalem : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Jerusalem : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Jerusalem : Shaarei Tzedek Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Jerusalem : Hadassah Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Kfar Saba : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kfar Saba : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kfar Saba : Meir Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Petach Tikva : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Petach Tikva : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Petach Tikva : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Petah Tikva : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Petah-Tikva : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Ramat Gan : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rehovot : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rehovot : Kaplan Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Tel Aviv : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tel Aviv : Tel Aviv Sourasky Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Tel Hashomer : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Tel Hashomer : Sheba Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Zerifin : Assaf Harofeh

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Italy

Firenze : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Firenze : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Messina : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Messina : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Milano : Instituto Clinico Humanitas IRCCS

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

View More »

Napoli : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Roma : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roma : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Roma : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Roma : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Roma : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Rome : Site Reference ID/Investigator# 38176

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rome : Site Reference ID/Investigator# 38178

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rozzano : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rozzano : Site Reference ID/Investigator# 38177

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Japan

Aichi : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aichi : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aichi : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Akita : Site Ref # / Investigator 81105

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Chiba : Toho University Sakura Medical Center

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

View More »

Chiba : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chiba : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Chiba : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Chikushino : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chikushino : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chikushino : Fukuoka University Chikushi Hospital

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chikushino : Site Ref # / Investigator 79700

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Fukuoka : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Fukuoka : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Fukuoka : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fukuoka : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Fukuoka : Site Ref # / Investigator 79643

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Fukuoka : Site Ref # / Investigator 79644

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Gifu : Site Ref # / Investigator 79694

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hamamatsu : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Hamamatsu : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamamatsu : Site Ref # / Investigator 79466

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hamamatsu : Site Ref # / Investigator 79645

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hirosaki : Site Ref # / Investigator 79642

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hiroshima : Site Ref # / Investigator 79477

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hokkaido : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hokkaido : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Hyogo : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hyogo : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Iwafune : Site Ref # / Investigator 79681

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kagoshima : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Kagoshima : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kagoshima : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kagoshima : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Kagoshima : Site Ref # / Investigator 79450

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kagoshima-Shi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Kagoshima-Shi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kashiwa : Site Ref # / Investigator 79675

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kashiwa : Site Ref # / Investigator 79478

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kawagoe : Site Ref # / Investigator 79693

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Koriyama : Site Ref # / Investigator 79454

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kumamoto : Site Ref # / Investigator 79445

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kurashiki : Site Ref # / Investigator 79636

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kurume : Research Site

Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

Kyoto : Site Ref # / Investigator 79475

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Minato : Site Ref # / Investigator 79456

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Miyagi : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Miyagi : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Miyagi : Site Ref # / Investigator 68736

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Morioka : Site Ref # / Investigator 79446

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagasaki : Site Ref # / Investigator 79656

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Site Ref # / Investigator 79654

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Site Ref # / Investigator 79653

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Neyagawa : Site Ref # / Investigator 79459

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nishinomiya : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Nishinomiya : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nishinomiya : Site Ref # / Investigator 79465

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Ohtsu : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Ohtsu : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oita : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Oita : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oita : Site Ref # / Investigator 79677

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Oita : Site Ref # / Investigator 79695

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Okayama : Site Ref # / Investigator 79479

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Osaka : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osaka : Osaka City University Hospital

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Osaka : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Osaka : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Osaka : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Osaka : Site Ref # / Investigator 79448

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Site Ref # / Investigator 79449

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Site Ref # / Investigator 79464

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka-City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Osaka-City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osakasayama : Site Ref # / Investigator 79657

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Otsu : Site Ref # / Investigator 79673

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Saga : Site Ref # / Investigator 79674

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Saitama : Site Ref # / Investigator 79455

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Sakura : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Sakura : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sakura : Site Ref # / Investigator 79476

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Sakura-Shi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Sakura-Shi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sapporo : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Sapporo : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sendai : National Hospital Organization Sendai Medlical Center

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Shinjuku : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Shinjuku : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Shunan : Site Ref # / Investigator 79453

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Suita : Site Ref # / Investigator 79634

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Takamatsu : Site Ref # / Investigator 79451

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Tokyo : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Tokyo : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tokyo : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tokyo : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Tokyo : Site Ref # / Investigator 79641

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Tokyo : Site Ref # / Investigator 79699

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Toyohashi : Site Ref # / Investigator 81102

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Toyota : Site Ref # / Investigator 81100

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Yokkaichi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Yokkaichi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Yokkaichi : Site Ref # / Investigator 79458

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Yokkaichi-Shi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Yokkaichi-Shi : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Yokohama : Site Ref # / Investigator 79473

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Korea, Republic of

Daegu : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Daegu : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Daegu : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Gyeonggi-Do : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Gyeonggi-Do : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Pusan : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Seoul : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Seoul : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : Severance Hospital, Yonsei University Health System

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Seoul : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Seoul : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Wonju : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Latvia

Latvia : Latvia

A Study of TRK-170 for the Treatment of Crohn's Disease

Netherlands

Alkmaar : Site Reference ID/Investigator# 38181

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Almere : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amersfoort : Site Reference ID/Investigator# 38179

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Amsterdam : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Amsterdam : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amsterdam : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Amsterdam : AMC

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Amsterdam : VUMC

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Amsterdam : Site Reference ID/Investigator# 43042

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : Pfizer Investigational Site

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs

Amsterdam : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Amsterdam : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Amsterdam Zuidoost : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Groningen : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Leiden : Site Reference ID/Investigator# 38180

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Maastricht : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Maastricht : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rotterdam : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Rotterdam : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rotterdam : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Rotterdam : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

The Netherlands : The Netherlands

A Study of TRK-170 for the Treatment of Crohn's Disease

Utrecht : UMCU

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

New Zealand

Christchurch : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Christchurch : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Christchurch : University of Otago

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Christchurch : University of Otago

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Dunedin : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Dunedin : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Grafton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamilton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Hamilton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamilton : Waikato Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Hamilton : Waikato Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Hastings : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lower Hutt : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Otahuhu : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Plenty : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tauranga. : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tauranga. : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Wellington : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Wellington : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Norway

Ålesund : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bergen : Department of Medicine, Haukeland University Hospital

Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease

Gjettum : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Norway : Norway

A Study of TRK-170 for the Treatment of Crohn's Disease

Rud : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

View More »

Tønsberg : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tønsberg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tromsø : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tromsø : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Poland

Bydgoszcz : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Bydgoszcz : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bydgoszcz : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bydgoszcz : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Elblag : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Elblag : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Krakow : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Kraków : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Kraków : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Lodz : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lodz : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Łódź : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Łódź : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Poland : Poland

A Study of TRK-170 for the Treatment of Crohn's Disease

Rzeszów : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Rzeszów : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Sopot : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Torun : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Warszawa : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Warszawa : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Warszawa : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Warszawa : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Wroclaw : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Wrocław : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Wrocław : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Puerto Rico

Ponce : Pharmaseek, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Ponce : Pharmaseek, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Romania

Bucuresti : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Romania : Romania

A Study of TRK-170 for the Treatment of Crohn's Disease

Russian Federation

Ekaterinburg : 013

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Ekaterinburg : 28

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Kazan : 016

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Kazan : 012

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Moscow : 007

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 008

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 009

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 011

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 014

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 005

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 24

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 25

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 31

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Nizhniy Novgorod : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Novgorod : 23

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Novosibirsk : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Orenburg : 29

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Orenburg : 20

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Orenburg : 21

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 006

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 001

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 003

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 004

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Samara : 015

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Samara : 18

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Shakhty : 017

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

St. Petersburg : 19

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Taganrog : 010

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Tolyatti : 26

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Ufa : 27

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Ufa : 22

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Ulyanovsk : 30

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Yaroslavl : 002

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Serbia

Belgrade : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Beograd : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nis : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Serbica : Serbia

A Study of TRK-170 for the Treatment of Crohn's Disease

Slovakia

Bratislava : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Bratislava : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Nitra : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Nitra : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Nitra : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

View More »

Nitra : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Nove Mesto nad Vahom : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Nove Mesto nad Vahom : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Nove Mesto nad Vahom : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Presov : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Presov : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Trnava : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

South Africa

Bellville : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bellville : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Cape Town : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Cape Town : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cape Town : Kingsbury Hospital

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

View More »

Claremont : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Claremont : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Claremont : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Durban : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Durban : Parklands Medical Centre

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Observatory : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Observatory : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Overport : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Overport : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Overport : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Pretoria : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Spain

Barcelona : Hospital Clinic de Barcelona

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Barcelona : Hospital Clinic de Barcelona

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Cordoba : Hospital Universitario Reina Sofia

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Elche : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Huelva : Hospital Juan Ramon Jimenez

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

View More »

Madrid : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Madrid : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Madrid : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Madrid : Hospital La Princesa

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital Clinico San Carlos

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital Universitario La Paz

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital 12 de Octubre

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Site Reference ID/Investigator# 38185

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Madrid : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Majadahonda : Pfizer Investigational Site

A Study To Monitor Long-Term Treatment With PF-00547659

Majadahonda : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Pontevedra : Hospital de Montecelo

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Sabadell : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sabadell : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Sabadell (Barcelona) : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Sabadell (Barcelona) : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Santiago De Compostela : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seville : Hospital Virgen del Rocio

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Valencia : Hospital Universitario La Fe

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Valencia : Hospital de Sagunto

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Sweden

Gothenburg : Site Reference ID/Investigator# 39065

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lund : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lund : Site Reference ID/Investigator# 39064

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lund : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Lund : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

View More »

Orebro : Site Reference ID/Investigator# 39066

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Stockholm : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Stockholm : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Sweden : Sweden

A Study of TRK-170 for the Treatment of Crohn's Disease

Uppsala : Site Reference ID/Investigator# 39082

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Switzerland

Bern : Site Reference ID/Investigator# 38192

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Zuerich : Novartis Investigative Site

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

Zurich :

A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

Zurich : Site Reference ID/Investigator# 38191

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Ukraine

Ukraine : Ukraine

A Study of TRK-170 for the Treatment of Crohn's Disease

United Kingdom

Birmingham : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Birmingham : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Birmingham : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Brighton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Brighton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Bristol : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Bristol : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bristol : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bristol : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bristol : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Cambridge : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Cambridge : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cardiff : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Edinburgh : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Edinburgh : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Edinburgh : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Exeter : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Glasgow : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Gloucester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Gloucester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Harrow : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Harrow : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Harrow : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Harrow : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Liverpool : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Liverpool : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

London : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

London : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

London : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Manchester : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Manchester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Manchester : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Manchester : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Newcastle upon Tyne : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Newcastle-upon-Tyne : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Newcastle-upon-Tyne : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Newcastle-upon-Tyne : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Norwich : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Norwich : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nottinghamshirecc : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Nottinghamshirecc : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oxford : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Oxford : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oxford : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Oxford : Site Reference ID/Investigator# 38196

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Oxford : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oxford : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Salford : GSK Investigational Site

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Salford : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Salford : GSK Investigational Site

Open-Label Extension Study of GSK1605786A

Shrewsbury : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Shropshire : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Southampton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Southampton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sy4 : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Worthing : Worthing Hospital

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)